Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment
Lowering of cardiovascular risk in treatment with liraglutide – Results of the LEADER

Česká verzia

Authors: Jindřich Olšovský
Authors place of work: II. interní klinika LF MU a FN U sv. Anny v Brně
Published in the journal: Vnitř Lék 2016; 62(7-8): 613-615
Category: Reviews

Summary

The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity–mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk.

Key words:
cardiovascular risk – LEADER – liraglutid – type 2 diabetes mellitus

Zdroje

1. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Int 2010; 170(14): 1191–1201.

2. Gilbert RE, Mann JF, Hanefeld M et al. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 2014; 57(7): 1325–1331.

3. Charbonnel B, Normandy J, Erdmann E et al. [PROactive Study Group]. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27(7): 1647–1653.

4. Scirica B, Braunwald E, Raz I et al. [SAVOR-TIMI 53 Steering Committee and Investigators]. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130(18): 1579–1588. Erratum in Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. [Circulation. 2015].

5. White WB, Kupfer S, Zannad F et al. [EXAMINE Investigators]. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care 2016; 39(7): 1267–1273.

6. Green JB, Betel MA, Armstrong PW et al. [TECOS Study Group]. The Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232–242.

7. Pfeffer MA, Claggett B, Diaz R et al. [ELIXA Investigators]. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373(23): 2247–2257.

8. Zinman B, Wanner Ch, Lachin JM et al. ]EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128.

9. Marso SP, Daniels GH, Brown-Frandsen K et al. [LEADER Steering Committee; LEADER Trial Investigators]. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322.